source
- STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drugSTAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
- NSF launches $47 million pilot to create joint university-industry Ph.D. programs for life scientistsThe National Science Foundation, with funding announced by the Trump administration, is testing a new Ph.D. training model that blends academic study with industry experience. The $47 million pilo…